Advisory Committee to the Director, Centers for Disease Control and Prevention, 67753-67754 [2023-21567]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2023–21566 Filed 9–29–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2023–0082]
Advisory Committee to the Director,
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with regulatory
provisions, the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
Advisory Committee to the Director,
Centers for Disease Control and
Prevention (ACD, CDC). This is a hybrid
meeting, accessible both in person and
virtually (webcast live via the World
Wide Web). It is open to the public and
limited only by the space available.
Time will be available for public
comment.
SUMMARY:
The meeting will be held on
November 14, 2023, from 9:00 a.m. to
4:00 p.m., EST (times subject to change).
Written comments must be received
on or before October 27, 2023.
ADDRESSES:
Meeting address: CDC Roybal
Campus, Building 19, Auditorium B3,
1600 Clifton Road NE, Atlanta, Georgia
30329–4027.
Please note that the meeting location,
the CDC Roybal Campus, is a federal
facility and in-person access is limited
to United States citizens unless prior
authorizations, taking up to 30 to 60
days, have been made. Visitors must
follow all directions for access to CDC
facilities. Directions for visitors to CDC,
including safety requirements related to
COVID–19; are available at https://
www.cdc.gov/screening/visitors.html.
lotter on DSK11XQN23PROD with NOTICES1
DATES:
VerDate Sep<11>2014
18:41 Sep 29, 2023
Jkt 262001
Registration: You must register to
attend this meeting in person. If you
wish to attend in person, please submit
a request by email to ACDirector@
cdc.gov or by telephone at (404) 345–
1039 at least 5 business days in advance
of the meeting. No registration is
required to view the meeting via the
World Wide Web. Information for
accessing the webcast will be available
at https://www.cdc.gov/about/advisorycommittee-director/.
Written comments: You may submit
comments, identified by Docket No.
CDC–2023–0082, by either of the
methods listed below. Do not submit
comments for the docket by email. CDC
does not accept comments for the
docket by email.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Bridget Richards, MPH,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE,
Mailstop H21–10, Atlanta, Georgia
30329–4027. Attn: Docket No. CDC–
2023–0082.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to https://www.regulations.gov,
including any personal information
provided. For access to the docket to
read background documents or
comments received, go to https://
www.regulations.gov. Written comments
received in advance of the meeting will
be included in the official record of the
meeting.
FOR FURTHER INFORMATION CONTACT:
Bridget Richards, MPH, Office of the
Chief of Staff, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop H21–10, Atlanta,
Georgia 30329–4027; Telephone: (404)
345–1039; Email: ACDirector@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee to
the Director, CDC, shall (1) make
recommendations to the Director
regarding ways to prioritize the
activities of the agency in alignment
with the CDC Strategic Plan required
under section 305(c); H.R. 2617–1252;
(2) advise on ways to achieve or
improve performance metrics in relation
to the CDC Strategic Plan, and other
relevant metrics, as appropriate; (3)
provide advice and recommendations
on the development of the Strategic
Plan, and any subsequent updates, as
appropriate; (4) advise on grant,
cooperative agreements, contracts, or
other transactions, as applicable; (5)
provide other advice to the Director, as
requested, to fulfill duties under
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
67753
sections 301 and 311; and (6) appoint
subcommittees. The Committee
recommends ways to prioritize CDC’s
activities, improve results, and address
health disparities. It also provides
guidance to help CDC work more
effectively with its various private and
public sector constituents to make
health protection a practical reality.
Matters to be Considered: The agenda
will include an introduction of the new
CDC Director, Dr. Mandy Cohen, and a
discussion regarding agency updates
and priorities. The agenda also includes
updates on the progress made to date on
the health equity, laboratory, and data
and surveillance recommendation;
discussion and vote on the Laboratory
Workgroup final recommendations; and
discussion and votes to sunset the
Health Equity and Laboratory
workgroups due to completion of their
terms of reference. CDC’s Senior
Advisor for Health Strategy will present
on supporting healthy families, and a
Senior Counselor to the CDC Director
will present on COVID–19 recission.
Agenda items are subject to change as
priorities dictate.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments on October 2, 2023 through
October 27, 2023.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
E:\FR\FM\02OCN1.SGM
02OCN1
67754
Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2023–21567 Filed 9–29–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2023–0080]
Guidelines for the Use of Doxycycline
Post-Exposure Prophylaxis for
Bacterial Sexually Transmitted
Infection (STI) Prevention; Request for
Comment and Informational
Presentation
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC) in the
Department of Health and Human
Services (HHS) announces the opening
of a docket to obtain comment on
proposed guidelines for the use of
doxycycline post-exposure prophylaxis
(PEP) for prevention of bacterial
sexually transmitted infections (STI).
The proposed guidelines for bacterial
STI prevention include post-exposure
prophylaxis with doxycycline
(doxycycline PEP) because it has
demonstrated benefit in reducing
chlamydia, gonorrhea, and syphilis
infections and represents a new
approach to addressing STI prevention
in populations at increased risk for
these infections. Doxycycline PEP,
when offered, should be implemented
in the context of a comprehensive
sexual health approach including risk
reduction counseling, STI screening and
treatment, recommended vaccination,
and linkage to HIV pre-exposure
prophylaxis (PrEP), HIV care, or other
services, as appropriate. The purpose of
the proposed guidelines is to provide
updated clinical guidance for healthcare
providers to inform the use of
doxycycline PEP for preventing
bacterial STI infections. CDC has made
available a pre-recorded informational
presentation to provide information
about the studies considered when
developing the proposed guideline,
explain the public comment process,
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:41 Sep 29, 2023
Jkt 262001
and provide an overview of important
monitoring for antibiotic use and
antibiotic resistance that the agency will
be considering to address potential
risks.
DATES: Written comments must be
received on or before November 16,
2023. An Informational Presentation has
been pre-recorded and is available at
https://npin.cdc.gov/.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2023–
0080 by either of the methods listed
below. Do not submit comments by
email. CDC does not accept comments
by email.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: [Division of STD Prevention,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE,
Mailstop US12–2, Atlanta, GA 30329,
Attn: Docket No. CDC–2023–0080].
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to https://regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
The informational presentation can be
accessed at https://npin.cdc.gov/.
FOR FURTHER INFORMATION CONTACT: John
R. Papp, Centers for Disease Control and
Prevention, 1600 Clifton Road NE,
Mailstop U12–3, Atlanta, GA 30329;
Telephone: 404–639–8000; Email:
jwp6@cdc.gov.
SUPPLEMENTARY INFORMATION: CDC’s
proposed guidelines for the use of postexposure prophylaxis with doxycycline
for bacterial STI prevention in the
United States is available under the
Supporting and Related Materials tab in
the docket for this notice, Docket No.
CDC–2023–0080, on https://
www.regulations.gov.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. In addition, CDC invites comments
specifically on the following questions
proposed in this Notice:
• Based on the evidence presented in
the full guidelines document (see the
Supporting and Related Materials tab in
the docket), does the evidence support
the proposed guidelines for the use of
post-exposure prophylaxis with
doxycycline for bacterial STI
prevention, including but not limited to
risks and benefits? If not, please state
the reason why and, if available,
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
provide additional evidence for
consideration.
• Are CDC’s proposed guidelines for
the use of post-exposure prophylaxis
with doxycycline bacterial STI
prevention clearly written? If not, what
changes do you propose to make it
clear?
• If implemented as currently drafted,
do you believe the proposed guidelines
for the use of post-exposure prophylaxis
with doxycycline for bacterial STI
prevention would result in improved
prevention of bacterial STIs in the
United States? If not, please provide an
explanation and supporting data or
evidence.
• How can these proposed guidelines
most effectively reach and be received
by populations who would benefit from
this intervention?
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comment or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information such
as Social Security numbers, medical
information, inappropriate language, or
duplicate/near duplicate examples of a
mass-mail campaign.
Background
Incidence of sexually transmitted
infections (STIs) caused by Neisseria
gonorrhoeae (causative agent of
gonorrhea), Chlamydia trachomatis
(causative agent of chlamydia), and
Treponema pallidum (causative agent of
syphilis) continues to increase in the
United States. Novel approaches are
needed to address the STI epidemic,
especially for populations
disproportionately affected (1). Postexposure prophylaxis (PEP) involves
taking a medication to prevent an
infection after a possible exposure and
is a common strategy for prevention of
HIV and other infections. PEP is a form
of chemoprophylaxis and distinct from
pre-exposure prophylaxis (PrEP) which
involves taking a medication before
exposure occurs. Doxycycline, a broadspectrum tetracycline antibiotic, is used
as pre- or post-exposure prophylaxis to
prevent infections such as malaria and
Lyme disease (2). Doxycycline is well
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 88, Number 189 (Monday, October 2, 2023)]
[Notices]
[Pages 67753-67754]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21567]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2023-0082]
Advisory Committee to the Director, Centers for Disease Control
and Prevention
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with regulatory provisions, the Centers for
Disease Control and Prevention (CDC) announces the following meeting of
the Advisory Committee to the Director, Centers for Disease Control and
Prevention (ACD, CDC). This is a hybrid meeting, accessible both in
person and virtually (webcast live via the World Wide Web). It is open
to the public and limited only by the space available. Time will be
available for public comment.
DATES: The meeting will be held on November 14, 2023, from 9:00 a.m. to
4:00 p.m., EST (times subject to change).
Written comments must be received on or before October 27, 2023.
ADDRESSES:
Meeting address: CDC Roybal Campus, Building 19, Auditorium B3,
1600 Clifton Road NE, Atlanta, Georgia 30329-4027.
Please note that the meeting location, the CDC Roybal Campus, is a
federal facility and in-person access is limited to United States
citizens unless prior authorizations, taking up to 30 to 60 days, have
been made. Visitors must follow all directions for access to CDC
facilities. Directions for visitors to CDC, including safety
requirements related to COVID-19; are available at https://www.cdc.gov/screening/visitors.html.
Registration: You must register to attend this meeting in person.
If you wish to attend in person, please submit a request by email to
[email protected] or by telephone at (404) 345-1039 at least 5
business days in advance of the meeting. No registration is required to
view the meeting via the World Wide Web. Information for accessing the
webcast will be available at https://www.cdc.gov/about/advisory-committee-director/.
Written comments: You may submit comments, identified by Docket No.
CDC-2023-0082, by either of the methods listed below. Do not submit
comments for the docket by email. CDC does not accept comments for the
docket by email.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Bridget Richards, MPH, Centers for Disease Control
and Prevention, 1600 Clifton Road NE, Mailstop H21-10, Atlanta, Georgia
30329-4027. Attn: Docket No. CDC-2023-0082.
Instructions: All submissions received must include the agency name
and Docket Number. All relevant comments received will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
Written comments received in advance of the meeting will be included in
the official record of the meeting.
FOR FURTHER INFORMATION CONTACT: Bridget Richards, MPH, Office of the
Chief of Staff, Centers for Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H21-10, Atlanta, Georgia 30329-4027;
Telephone: (404) 345-1039; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee to the Director, CDC, shall (1)
make recommendations to the Director regarding ways to prioritize the
activities of the agency in alignment with the CDC Strategic Plan
required under section 305(c); H.R. 2617-1252; (2) advise on ways to
achieve or improve performance metrics in relation to the CDC Strategic
Plan, and other relevant metrics, as appropriate; (3) provide advice
and recommendations on the development of the Strategic Plan, and any
subsequent updates, as appropriate; (4) advise on grant, cooperative
agreements, contracts, or other transactions, as applicable; (5)
provide other advice to the Director, as requested, to fulfill duties
under sections 301 and 311; and (6) appoint subcommittees. The
Committee recommends ways to prioritize CDC's activities, improve
results, and address health disparities. It also provides guidance to
help CDC work more effectively with its various private and public
sector constituents to make health protection a practical reality.
Matters to be Considered: The agenda will include an introduction
of the new CDC Director, Dr. Mandy Cohen, and a discussion regarding
agency updates and priorities. The agenda also includes updates on the
progress made to date on the health equity, laboratory, and data and
surveillance recommendation; discussion and vote on the Laboratory
Workgroup final recommendations; and discussion and votes to sunset the
Health Equity and Laboratory workgroups due to completion of their
terms of reference. CDC's Senior Advisor for Health Strategy will
present on supporting healthy families, and a Senior Counselor to the
CDC Director will present on COVID-19 recission. Agenda items are
subject to change as priorities dictate.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: The docket will be opened to receive
written comments on October 2, 2023 through October 27, 2023.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other
[[Page 67754]]
committee management activities, for both the Centers for Disease
Control and Prevention and the Agency for Toxic Substances and Disease
Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-21567 Filed 9-29-23; 8:45 am]
BILLING CODE 4163-18-P
